Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Boxer Capital
AddedFeb 13, 2024
UpdatedJul 11, 2026
Boxer Capital

Boxer Capital

Operating

Boxer Capital, LLC: A private fund investing and innovating in diverse biotechnology sectors.

Location
San Diego, CA, US
Founded
2005
Firm
Compare
Portfolio
Employees
Website

Investments

Flare Therapeutics
Flare Therapeutics
Series C

Total Raised

$290M

Rounds

3

Series C$85MJune 2026
Series B$123MMarch 2023
Series A$82MMay 2021
Seismic Therapeutic
Seismic Therapeutic

Total Raised

$222M

Rounds

2

Series B$121MDecember 2023
Series A$101MFebruary 2022
Arvinas
Arvinas
Public

Total Raised

$461.6M

Rounds

5

Post Ipo Equity$350MNovember 2023
Lusaris Therapeutics
Lusaris Therapeutics

Total Raised

$60M

Rounds

1

Series A$60MNovember 2022
Alterome Therapeutics
Alterome Therapeutics

Total Raised

$99M

Rounds

2

Series A$35MNovember 2022
Series A$64MJanuary 2022
SpringWorks Therapeutics
SpringWorks Therapeutics
Public

Total Raised

$1B

Rounds

6

Post Ipo Equity$225MSeptember 2022
Incyclix Bio
Incyclix Bio

Total Raised

$36M

Rounds

2

Series B$30MMarch 2022
2seventy bio
2seventy bio
Public

Total Raised

$315M

Rounds

4

Post Ipo Equity$170MMarch 2022
Ceptur Therapeutics
Ceptur Therapeutics

Total Raised

$81.2M

Rounds

2

Series A$75MJanuary 2022
Shoreline Biosciences
Shoreline Biosciences

Total Raised

$186M

Rounds

3

Series B$140MNovember 2021
Series A$43MFebruary 2021
Asher Bio
Asher Bio

Total Raised

$163.2M

Rounds

3

Series B$108MSeptember 2021
Series A$55MMarch 2021
Tango Therapeutics
Tango Therapeutics
Public

Total Raised

$351M

Rounds

5

Post Ipo Equity$186MAugust 2021
Ajax Therapeutics
Ajax Therapeutics

Total Raised

$40M

Rounds

1

Series Unknown$40MJune 2021
Boundless Bio
Boundless Bio

Total Raised

$251.4M

Rounds

3

Series B$105MApril 2021
Vividion Therapeutics
Vividion Therapeutics
Acquired

Total Raised

$371.5M

Rounds

5

Series C$135MFebruary 2021
Scorpion Therapeutics
Scorpion Therapeutics

Total Raised

$270M

Rounds

2

Series B$162MJanuary 2021
Cullinan Oncology
Cullinan Oncology
Public

Total Raised

$389.7M

Rounds

5

Series C$131.2MDecember 2020
Vivace Therapeutics
Vivace Therapeutics

Total Raised

$70M

Rounds

3

Series C$30MDecember 2020
Solid Biosciences
Solid Biosciences
Public

Total Raised

$441.3M

Rounds

8

Post Ipo Equity$90MDecember 2020